Comparison between mono-tacrolimus and mono-glucocorticoid in the treatment of myasthenia gravis.

ABSTRACT:

Objective

Use of tacrolimus in mild to moderate myasthenia gravis (MG) is generally limited to glucocorticoid-refractory cases; the advantage of mono-tacrolimus over mono-glucocorticoids is unknown.

Methods

We included mild to moderate MG patients treated with mono-tacrolimus (mono-TAC) or mono-glucocorticoids (mono-GC). The correlation between the immunotherapy options and the treatment efficacy and side effects were examined in 1:1 propensity-score matching. The main outcome was time to minimal manifestations status or better (MMS or better). Secondary outcomes include time to relapse, the mean changes in Myasthenia Gravis-specific Activities of Daily Living (MG-ADL) scores and the rate of adverse events.

Results

Baseline characteristics showed no difference between

SUBMITTER: Fan Z 

PROVIDER: S-EPMC10109324 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature